{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:26:41Z","timestamp":1794580001213,"version":"4.9.1"},"reference-count":81,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":175,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["MRFF 2025006"],"award-info":[{"award-number":["MRFF 2025006"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2025,11,9]]},"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Targeting progressive multiple sclerosis (MS) addresses the current single biggest unmet need in the MS therapeutic landscape and anti-Epstein-Barr virus (EBV) therapy potentially strikes at the root cause. The SpironolacTone and famciclOvir in the treatment of Progressive MS to prevent disability progression (STOP-MS) trial has been developed to assess anti-EBV therapies in the treatment of progressive MS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>STOP-MS is a multi-arm, multi-stage, randomised, double-blind, placebo-controlled trial testing spironolactone and famciclovir to prevent disability progression in MS. Australians with progressive forms of MS, aged 25 to 70 years with established disability, are eligible. Recruitment commenced in March 2025 and the first participant was enrolled on 15 April 2025. The sample size for STOP-MS is 150 in stage 1 and 300 in stage 2. In stage 1, the composite primary outcome measures will be reduction of EBV DNA in saliva and serum EBV nuclear antigen-1 antibody titres. Minimum criteria for consideration of progression to stage 2 will be a 10% reduction in the composite outcome measure. In stage 2, the primary outcome measure will be 6-month confirmed disability progression analysed using Cox-proportional hazards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>The STOP-MS trial has been acknowledged by the Therapeutics Goods Administration under the Clinical Trial Notification scheme (CT-2023-CTN-03\u2009505-1) and is registered with the Australian and New Zealand Clinical Trial Registry (ACTRN12623000849695).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001313","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:35:21Z","timestamp":1766518521000},"page":"e001313","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-0529","authenticated-orcid":false,"given":"Kayla","family":"Ward","sequence":"first","affiliation":[{"name":"School of Medicine and Dentistry, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"},{"name":"Department of Neurology, Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivien","family":"Li","sequence":"additional","affiliation":[{"name":"The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[{"name":"Translational Neuroimmunology Group, Kids Neuroscience Centre and ANZAC Research Institute, The University of Sydney Sydney Medical School, Sydney, New South Wales, Australia"},{"name":"Department of Neurology, Concord Hospital, Concord, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2266-7465","authenticated-orcid":false,"given":"Lesley-Ann","family":"Hall","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre, Flinders University, Adelaide, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[{"name":"Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaylene","family":"Young","sequence":"additional","affiliation":[{"name":"Menzies Institute for Medical Research, University of Tasmania, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Mckay","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Australia, Multiple Sclerosis Australia, Summer Hill, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8023-2992","authenticated-orcid":false,"given":"Vanessa","family":"Vigar","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"},{"name":"National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Oishi","sequence":"additional","affiliation":[{"name":"School of Medicine, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-4546","authenticated-orcid":false,"given":"Lidia","family":"Madrid San Martin","sequence":"additional","affiliation":[{"name":"School of Medicine and Dentistry, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Kaskow","sequence":"additional","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2898-0253","authenticated-orcid":false,"given":"Grant","family":"Parnell","sequence":"additional","affiliation":[{"name":"Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, Westmead, New South Wales, Australia"},{"name":"Infection, Immunity and Inflammation Group, School of Medical Sciences, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-6758","authenticated-orcid":false,"given":"Julie A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"University of Tasmania Menzies Institute for Medical Research, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0097-2438","authenticated-orcid":false,"given":"Jing","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Medicine and Dentistry, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"},{"name":"Rural Health Research Institute, Charles Sturt University, Albury, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Smith","sequence":"additional","affiliation":[{"name":"QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3942-4340","authenticated-orcid":false,"given":"Vilija","family":"Jokubaitis","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Monash University Central Clinical School, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"CORe, The University of Melbourne Department of Medicine RMH, Parkville, Victoria, Australia"},{"name":"Department of Neurology, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9172","authenticated-orcid":false,"given":"David","family":"Tscharke","sequence":"additional","affiliation":[{"name":"Immunology and Infectious Diseases, Australian National University The John Curtin School of Medical Research, Canberra, Australian Capital Territory, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Potter","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Australia, Summer Hill, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Brady","sequence":"additional","affiliation":[{"name":"Multiple Sclerosis Australia, Summer Hill, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[{"name":"Department of Neurology, John Hunter Hospital, New Lambton Heights, New South Wales, Australia"},{"name":"The University of Newcastle Hunter Medical Research Institute, New Lambton, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Steinman","sequence":"additional","affiliation":[{"name":"Departments of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0166-1700","authenticated-orcid":false,"given":"Mahesh","family":"Parmar","sequence":"additional","affiliation":[{"name":"ACORD at MRC Clinical Trials Unit, University College London Institute of Clinical Trials and Methodology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7286-6901","authenticated-orcid":false,"given":"Jeremy","family":"Chataway","sequence":"additional","affiliation":[{"name":"ACORD at MRC Clinical Trials Unit, University College London Institute of Clinical Trials and Methodology, London, UK"},{"name":"NIHR University College London Hospitals Biomedical Research Centre, London, UK"},{"name":"Queen Square Multiple Sclerosis Centre, Department of Inflammation, UCL Queen Square Institute of Neurology, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-3172","authenticated-orcid":false,"given":"Todd","family":"Hardy","sequence":"additional","affiliation":[{"name":"Department of Neurology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"},{"name":"The University of Sydney Brain and Mind Centre, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-548X","authenticated-orcid":false,"given":"William M.","family":"Carroll","sequence":"additional","affiliation":[{"name":"Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia"},{"name":"Department of Neurology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-8864","authenticated-orcid":false,"given":"Michael H.","family":"Barnett","sequence":"additional","affiliation":[{"name":"The University of Sydney Brain and Mind Centre, Camperdown, New South Wales, Australia"},{"name":"The University of Sydney Sydney Medical School, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0070","authenticated-orcid":false,"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[{"name":"University of Tasmania Menzies Institute for Medical Research, Hobart, Tasmania, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-4307","authenticated-orcid":false,"given":"Simon A.","family":"Broadley","sequence":"additional","affiliation":[{"name":"School of Medicine and Dentistry, Griffith University - Gold Coast Campus, Southport, Queensland, Australia"},{"name":"Department of Neurology, Gold Coast University Hospital, Southport, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"2025122311351521000_7.2.e001313.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"2025122311351521000_7.2.e001313.2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-444-52001-2.00014-5"},{"key":"2025122311351521000_7.2.e001313.3","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507084264"},{"key":"2025122311351521000_7.2.e001313.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70243-0"},{"key":"2025122311351521000_7.2.e001313.5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"key":"2025122311351521000_7.2.e001313.6","unstructured":"Ahmad H , Palmer AJ , Campbell JA , et al . Health economic impact of multiple sclerosis in Australia in 2021. Sydney, Australia: Menzies Institute for Medical Research, University of Tasmania, 2023."},{"key":"2025122311351521000_7.2.e001313.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w"},{"key":"2025122311351521000_7.2.e001313.8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00027-9"},{"key":"2025122311351521000_7.2.e001313.9","article-title":"Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta-analysis","volume":"9","author":"Ridley","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2025122311351521000_7.2.e001313.10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S1474-4422(25)00238-8","article-title":"Bruton\u2019s tyrosine kinase inhibitors for multiple sclerosis","volume":"24","author":"Airas","year":"2025","journal-title":"Lancet Neurol"},{"key":"2025122311351521000_7.2.e001313.11","doi-asserted-by":"crossref","unstructured":"Patsopoulos NA , Baranzini SE , Santaniello A , et al . Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019;365. doi:10.1126\/science.aav7188","DOI":"10.1126\/science.aav7188"},{"key":"2025122311351521000_7.2.e001313.12","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.2013.865866"},{"key":"2025122311351521000_7.2.e001313.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"key":"2025122311351521000_7.2.e001313.14","doi-asserted-by":"publisher","DOI":"10.1097\/00001648-200105000-00009"},{"key":"2025122311351521000_7.2.e001313.15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1352458520907901","article-title":"Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors","volume":"26","author":"Jacobs","year":"2020","journal-title":"Mult Scler"},{"key":"2025122311351521000_7.2.e001313.16","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj8222"},{"key":"2025122311351521000_7.2.e001313.17","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000308","article-title":"Time correlation between mononucleosis and initial symptoms of MS","volume":"4","author":"Endriz","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025122311351521000_7.2.e001313.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00543-7"},{"key":"2025122311351521000_7.2.e001313.19","doi-asserted-by":"publisher","DOI":"10.1097\/NEN.0b013e31827bfc62"},{"key":"2025122311351521000_7.2.e001313.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8496-1"},{"key":"2025122311351521000_7.2.e001313.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21886"},{"key":"2025122311351521000_7.2.e001313.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04432-7"},{"key":"2025122311351521000_7.2.e001313.23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1902623116"},{"key":"2025122311351521000_7.2.e001313.24","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3032","article-title":"Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis","volume":"9","author":"Thomas","year":"2023","journal-title":"Sci Adv"},{"key":"2025122311351521000_7.2.e001313.25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072397"},{"key":"2025122311351521000_7.2.e001313.26","first-page":"625","article-title":"Drugs in development for relapsing multiple sclerosis","volume":"73","author":"Ali","year":"2013","journal-title":"Drugs (Abingdon Engl)"},{"key":"2025122311351521000_7.2.e001313.27","doi-asserted-by":"crossref","first-page":"104377","DOI":"10.1016\/j.msard.2022.104377","article-title":"Effect of teriflunomide on Epstein-Barr virus shedding in relapsing-remitting multiple sclerosis patients: Outcomes from a real-world pilot cohort study","volume":"68","author":"Gold","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2025122311351521000_7.2.e001313.28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060197","article-title":"Antiviral Drugs for EBV","volume":"10","author":"Pagano","year":"2018","journal-title":"Cancers (Basel)"},{"key":"2025122311351521000_7.2.e001313.29","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.31"},{"key":"2025122311351521000_7.2.e001313.30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s40263-024-01153-5","article-title":"Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach","volume":"39","author":"Li","year":"2025","journal-title":"CNS Drugs"},{"key":"2025122311351521000_7.2.e001313.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1523686113"},{"key":"2025122311351521000_7.2.e001313.32","first-page":"217","article-title":"Pilot study on the efficacy of high doses of aldosterone and spirolactone derivatives in the treatment of multiple sclerosis","volume":"202","author":"Mertin","year":"1972","journal-title":"Z Neurol"},{"key":"2025122311351521000_7.2.e001313.33","doi-asserted-by":"publisher","DOI":"10.1021\/jm00128a012"},{"key":"2025122311351521000_7.2.e001313.34","doi-asserted-by":"publisher","DOI":"10.1191\/1352458505ms1185oa"},{"key":"2025122311351521000_7.2.e001313.35","doi-asserted-by":"publisher","DOI":"10.1177\/095632029500600203"},{"key":"2025122311351521000_7.2.e001313.36","doi-asserted-by":"crossref","unstructured":"Dobson R , Holden D , Vickaryous N , et al . A phase II open-label clinical trial to determine the effect of famciclovir on Epstein-Barr virus activity as measured by EBV shedding in the saliva of patients with multiple sclerosis. medRxiv 2023. doi:10.1101\/2023.08.18.23294265","DOI":"10.1101\/2023.08.18.23294265"},{"key":"2025122311351521000_7.2.e001313.37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025122311351521000_7.2.e001313.38","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419859183","article-title":"The feasibility, reliability and concurrent validity of the MSReactor computerized cognitive screening tool in multiple sclerosis","volume":"12","author":"Merlo","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"2025122311351521000_7.2.e001313.39","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30470-2"},{"key":"2025122311351521000_7.2.e001313.40","doi-asserted-by":"publisher","DOI":"10.2174\/18715273113126660177"},{"key":"2025122311351521000_7.2.e001313.41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2000625117"},{"key":"2025122311351521000_7.2.e001313.42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.36518\/2689-0216.1241","article-title":"Lymphoproliferative Disease in a Non-Transplant Patient and Spironolactone\u2019s Activity Against Epstein Barr Virus","volume":"2","author":"DeRenzi","year":"2021","journal-title":"HCA Healthc J Med"},{"key":"2025122311351521000_7.2.e001313.43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/095632029300401S01","article-title":"Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern","volume":"4","author":"Boyd","year":"1993","journal-title":"Antivir Chem Chemother"},{"key":"2025122311351521000_7.2.e001313.44","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.7.1599"},{"key":"2025122311351521000_7.2.e001313.45","doi-asserted-by":"publisher","DOI":"10.1177\/095632029700800311"},{"key":"2025122311351521000_7.2.e001313.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2010.07.008"},{"key":"2025122311351521000_7.2.e001313.47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1053\/jinf.2001.0954","article-title":"Treatment of severe infectious mononucleosis with famciclovir","volume":"44","author":"Goldani","year":"2002","journal-title":"J Infect"},{"key":"2025122311351521000_7.2.e001313.48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1212\/WNL.58.1.31","article-title":"A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS","volume":"58","author":"Bech","year":"2002","journal-title":"Neurology (ECronicon)"},{"key":"2025122311351521000_7.2.e001313.49","doi-asserted-by":"publisher","DOI":"10.1007\/BF00868517"},{"key":"2025122311351521000_7.2.e001313.50","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.1.119"},{"key":"2025122311351521000_7.2.e001313.51","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1517\/14740338.2010.485189","article-title":"Famciclovir: a focus on efficacy and safety","volume":"9","author":"Mubareka","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"2025122311351521000_7.2.e001313.52","doi-asserted-by":"publisher","DOI":"10.1177\/120347540300700603"},{"key":"2025122311351521000_7.2.e001313.53","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440240109016"},{"key":"2025122311351521000_7.2.e001313.54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0166-3542(95)00941-8","article-title":"Famciclovir: review of clinical efficacy and safety","volume":"29","author":"Cirelli","year":"1996","journal-title":"Antiviral Res"},{"key":"2025122311351521000_7.2.e001313.55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"2025122311351521000_7.2.e001313.56","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(87)91340-7","article-title":"Spironolactone and hyperkalaemia in patients with impaired renal failure","volume":"2","author":"McGeown","year":"1987","journal-title":"Lancet"},{"key":"2025122311351521000_7.2.e001313.57","unstructured":"Semaan JR , Parmar M . Famciclovir. Treasure Island (FL) ineligible companies. Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies: StatPearls, 2024."},{"key":"2025122311351521000_7.2.e001313.58","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4081\/aiua.2021.4.489","article-title":"Drug-induced gynecomastia: A systematic review and meta-analysis of randomized clinical trials","volume":"93","author":"Trinchieri","year":"2021","journal-title":"Arch Ital Urol Androl"},{"key":"2025122311351521000_7.2.e001313.59","doi-asserted-by":"crossref","DOI":"10.3390\/ph16071031","article-title":"Lower Urinary Tract Disorders as Adverse Drug Reactions-A Literature Review","volume":"16","author":"Dobrek","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025122311351521000_7.2.e001313.60","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14740338.2024.2442519","article-title":"Congenital anomalies associated with the use of cardiovascular drugs during pregnancy: a large-scale data analysis from the FAERS database","volume":"24","author":"Zheng","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2025122311351521000_7.2.e001313.61","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1206"},{"key":"2025122311351521000_7.2.e001313.62","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/dth.12069","article-title":"Dermatological medication effects on male fertility","volume":"26","author":"Millsop","year":"2013","journal-title":"Dermatol Ther"},{"key":"2025122311351521000_7.2.e001313.63","unstructured":"US Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE). Version 5.0 ed. Washington, DC, US; 2017."},{"key":"2025122311351521000_7.2.e001313.64","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7027.364"},{"key":"2025122311351521000_7.2.e001313.65","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"2025122311351521000_7.2.e001313.66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"2025122311351521000_7.2.e001313.67","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/brain\/122.5.871","article-title":"Development of a multiple sclerosis functional composite as a clinical trial outcome measure","volume":"122 (Pt 5)","author":"Cutter","year":"1999","journal-title":"Brain (Bacau)"},{"key":"2025122311351521000_7.2.e001313.68","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600411"},{"key":"2025122311351521000_7.2.e001313.69","first-page":"850","article-title":"Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests","volume":"69","author":"Goodkin","year":"1988","journal-title":"Arch Phys Med Rehabil"},{"key":"2025122311351521000_7.2.e001313.70","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517690821"},{"key":"2025122311351521000_7.2.e001313.71","doi-asserted-by":"publisher","DOI":"10.2466\/pms.1977.44.2.367"},{"key":"2025122311351521000_7.2.e001313.72","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/124.5.962"},{"key":"2025122311351521000_7.2.e001313.73","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1212\/01.WNL.0000127604.84575.0D","article-title":"Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12)","volume":"62","author":"McGuigan","year":"2004","journal-title":"Neurology (ECronicon)"},{"key":"2025122311351521000_7.2.e001313.74","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e31805d0c5d"},{"key":"2025122311351521000_7.2.e001313.75","unstructured":"Ritvo PG , Fischer JS , Miller DM , et al . Multiple sclerosis Q uality of life inventory: a user's manual. New York, NY, US, 1997."},{"key":"2025122311351521000_7.2.e001313.76","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11136-022-03214-y","article-title":"Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia","volume":"32","author":"Campbell","year":"2023","journal-title":"Qual Life Res"},{"key":"2025122311351521000_7.2.e001313.77","unstructured":"Campbell J , Mei I , Taylor B , et al . Health economic impact report of multiple sclerosis in Australia in 2017. Sydney, Australia: Menzies Institute for Medical Research, 2018."},{"key":"2025122311351521000_7.2.e001313.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"2025122311351521000_7.2.e001313.79","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03339.x"},{"key":"2025122311351521000_7.2.e001313.80","doi-asserted-by":"publisher","DOI":"10.3109\/03602537808993782"},{"key":"2025122311351521000_7.2.e001313.81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/cpt1976192170","article-title":"Bioavailability","volume":"19","author":"Karim","year":"1976","journal-title":"Clin Pharmacol Ther"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T19:35:25Z","timestamp":1766518525000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":81,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,12,23]]},"published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1136\/bmjno-2025-001313"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001313","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}